Cited by 435Parkinson's Disease Mechanisms and TreatmentsMitochondrial Function and PathologyCoenzyme Q10 studies and effects

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

Haas, Richard H., Nasirian, Fatemeh, Nakano, Kazutoshi, Ward, David, Pay, Mary, Hill, Robert, Shults, Clifford W.·1995·Annals of Neurology

DOI 10.1002/ana.410370604

Open this paper in CoChat — free account

Abstract

Following the discovery of inhibition of electron transport complex I by the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP), which produces a parkinsonian syndrome in humans, monkeys, and mice, several laboratories have reported abnormalities of complex I and other electron transport complexes (ETCs) in various tissues from patients with Parkinson's disease (PD). Criticism of the significance of these findings in the etiology of PD has centered on whether drug treatments or the debilitation of the disease process itself produced the low ETC activities. We present results from a blinded study of platelet mitochondrial ETC activities in 18 early untreated PD patients and 18 age‐ and sex‐matched controls and in 13 spousal controls. Lower complex I activity in platelet mitochondria of PD patients was seen in early untreated disease and thus cannot be due to debilitation or drug therapy. Home environmental factors seem an unlikely explanation for the reduced complex I activity in PD patients but have not been excluded. Complex II/III activity was also reduced by 20% in PD compared with age‐/sex‐matched controls. The low complex I and II/III activities in platelet mitochondria appear to be related to the etiology of PD.

Integrity signals

Registry

Crossref · 10.1002/ana.410370604

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,757
Abnormalities of the electron transport chain in idiopathic parkinson's disease
Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757
CENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL
Scoppetta, C., & Vaccario, M. L. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 755
Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease
Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., SATO, T. A., Oya, H., Ozawa, T., & Kagawa, Y. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91141-8 · Cited by 735
Spectrophotometric Assay of Cytochrome c Oxidase
Smith, L. (1955) · Methods of biochemical analysis · doi:10.1002/9780470110188.ch13 · Cited by 506
Mitochondrial DNA Variants Observed in Alzheimer Disease and Parkinson Disease Patients
Shoffner, J. M., Brown, M. D., Torroni, A., Lott, M. T., Cabell, M. F., Mirra, S. S., Beal, M. F., Yang, C.-C., Gearing, M., Salvo, R., et al. (1993) · Genomics · doi:10.1006/geno.1993.1299 · Cited by 450

Show all 47 references

Research works printed but not linked: 1

Lang AET, 1989, Quantification of neurological deficit, 289

Sorted by citations

Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
Mechanism of Toxicity in Rotenone Models of Parkinson's Disease
Sherer, T., Betarbet, R. S., Testa, C. M., Seo, B. B., Richardson, J. R., Kim, J. H., Miller, G. W., Yagi, T., Matsuno‐Yagi, A., & Greenamyre, J. T. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10756.2003 · Cited by 1,102
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Self-citation
Mitochondrial dysfunction and oxidative stress in Parkinson's disease
Subramaniam, S., & Chesselet, M. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.004 · Cited by 953
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Oxidative stress and Parkinson’s disease
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang‐James, Y., Kim, P. D., Hauser, M. A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001059 · Cited by 868
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
Henchcliffe, C., & Beal, M. F. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0924 · Cited by 798
Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation
Sherer, T., Kim, J.-H., Betarbet, R. S., & Greenamyre, J. T. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8072 · Cited by 719
Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress
Gautier, C. A., Kitada, T., & Shen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802076105 · Cited by 698
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Origin and functional consequences of the complex I defect in Parkinson's disease
Swerdlow, R. H., Parks, J. K., Miller, S. W., Davis, R. E., Tuttle, J. B., Trimmer, P. A., Sheehan, J. P., Bennett, J. P., & Parker, W. D. (1996) · Annals of Neurology · doi:10.1002/ana.410400417 · Cited by 638
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 652
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318797 · Cited by 497
Lewy bodies
Shults, C. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509567103 · Cited by 495
Self-citation
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
The MPTP Story
Langston, J. W. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-179006 · Cited by 457
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 426
Metabolomic profiling to develop blood biomarkers for Parkinson's disease
Bogdanov, M. B., Matson, W. R., Wang, L., Matson, T., Saunders-Pullman, R. J., Bressman, S., & Beal, M. F. (2008) · Brain · doi:10.1093/brain/awm304 · Cited by 402
Glutathione, iron and Parkinson’s disease
Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., & Andersen, J. K. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01174-7 · Cited by 394
Complex I deficiency in Parkinson's disease frontal cortex
Parker, W. D., Parks, J. K., & Swerdlow, R. H. (2007) · Brain Research · doi:10.1016/j.brainres.2007.10.061 · Cited by 392
The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer’s Disease and Parkinson’s Disease
Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378
Mitochondria in Neurodegeneration: Acute Ischemia and Chronic Neurodegenerative Diseases
Fiskum, G. M., Murphy, A. N., & Beal, M. F. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199904000-00001 · Cited by 354
Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson’s disease
Sherer, T., Richardson, J. R., Testa, C. M., Seo, B. B., Panov, A. V., Yagi, T., Matsuno‐Yagi, A., Miller, G. W., & Greenamyre, J. T. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04333.x · Cited by 348
Complex I and Parkinson's Disease
Greenamyre, J. T., Sherer, T., Betarbet, R. S., & Panov, A. V. (2001) · IUBMB Life · doi:10.1080/15216540152845939 · Cited by 343
Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review)
Guo, J., Zhao, X., Li, Y., Li, G., & Liu, X. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3406 · Cited by 353
Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease
Osellame, L. D., Rahim, A. A., Hargreaves, I. P., Gegg, M. E., Richard-Loendt, A., Brandner, S., Waddington, S. N., Schapira, A. H. V., & Duchen, M. R. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.014 · Cited by 338
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease
Büeler, H. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.006 · Cited by 332
Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects
Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
Self-citation
Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease
Gu, M., Cooper, J. A. D., Taanman, J., & Schapira, A. H. V. (1998) · Annals of Neurology · doi:10.1002/ana.410440207 · Cited by 313
The Role of Mitochondria in Reactive Oxygen Species Generation and Its Implications for Neurodegenerative Diseases
Kausar, S., Wang, F., & Cui, H. (2018) · Cells · doi:10.3390/cells7120274 · Cited by 327
Mitochondrial involvement in Parkinson’s disease, Huntington’s disease, hereditary spastic paraplegia and Friedreich’s ataxia
Schapira, A. H. V. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00164-9 · Cited by 306
Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures
Testa, C. M., Sherer, T., & Greenamyre, J. T. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.11.007 · Cited by 296
Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP111-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E. M., & Masliah, E. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00342-x · Cited by 301
Self-citation
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
The rotenone model of Parkinson's disease: genes, environment and mitochondria
Greenamyre, J. T., Betarbet, R. S., & Sherer, T. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(03)00023-3 · Cited by 265
Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice
Beal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256
Self-citation
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis
Banerjee, R., Starkov, A. A., Beal, M. F., & Thomas, B. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.007 · Cited by 262
Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity
Jha, N., Jurma, O. P., Lalli, G., Liu, Y., Pettus, E. H., Greenamyre, J. T., Liu, R.-M., Forman, H. J., & Andersen, J. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000120200 · Cited by 252
Alternative Mitochondrial Electron Transfer as a Novel Strategy for Neuroprotection
Wen, Y., Li, W., Poteet, E. C., Xie, L., Tan, C., Yan, L., Ju, X., Liu, R., Qian, H., Marvin, M. A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.208447 · Cited by 256
Etiology of Parkinson’s disease
Schapira, A. H. V. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s10 · Cited by 251
Dietary Antioxidants and Parkinson Disease
de Rijk, M. C. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550180070015 · Cited by 250
Mitochondrial dysfunction in Parkinson's disease
Greenamyre, J. T., MacKenzie, G. M., Peng, T., & Stephans, S. E. (1999) · Biochemical Society Symposia · doi:10.1042/bss0660085 · Cited by 248
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
Morris, G., & Berk, M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0310-y · Cited by 245
Manganese ethylene‐bis‐dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction
Zhang, J., Fitsanakis, V. A., Gu, G., Jing, D., Ao, M., Amarnath, V., & Montine, T. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01525.x · Cited by 238
Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations
Müftüoğlu, M., Elibol, B., Dalmızrak, Ö., Ercan, A., Kulaksiz-Erkmen, G., Öğüş, İ. H., Dalkara, T., & Özer, N. (2003) · Movement Disorders · doi:10.1002/mds.10695 · Cited by 247
Bioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease
Holper, L., Ben‐Shachar, D., & Mann, J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0090-0 · Cited by 236
Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone
Fleming, S. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.023 · Cited by 230
Proteomic Identification of a Stress Protein, Mortalin/mthsp70/GRP75
Jin, J., Hulette, C., Wang, Y., Zhang, T., Pan, C., Wadhwa, R., & Zhang, J. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500382-mcp200 · Cited by 228
The role of Coenzyme Q in mitochondrial electron transport
Lenaz, G., Fato, R., Formiggini, G., & Genova, M. L. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.009 · Cited by 230
NF-κB-Mediated Neuroinflammation in Parkinson’s Disease and Potential Therapeutic Effect of Polyphenols
Singh, S. S., Nand, S., Birla, H., Zahra, W., Singh, S. P., & Singh, S. P. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00147-2 · Cited by 217
Apoptotic signaling in dopamine‐induced cell death: the role of oxidative stress, p38 mitogen‐activated protein kinase, cytochrome c and caspases
Junn, E., & Mouradian, M. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00425.x · Cited by 214
Pesticides and Parkinson's disease
Couteur, D. G. L., McLean, A. J., Taylor, M. C., Woodham, B. L., & Philip G. Board (1999) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(99)80077-8 · Cited by 219
Glutathione and Parkinson's disease: Is this the elephant in the room?
Zeevalk, G. D., Razmpour, R., & Bernard, L. P. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.01.017 · Cited by 217
Mitochondrial dysfunction in neurodegenerative disorders
Schapira, A. H. V. (1998) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00115-7 · Cited by 213
Role of Platelet Mitochondria: Life in a Nucleus-Free Zone
Melchinger, H., Jain, K., Tyagi, T., & Hwa, J. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00153 · Cited by 208
Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease
Müller, T. H., Büttner, T., Gholipour, A.-F., & Kuhn, W. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00185-x · Cited by 203
Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection
Ahmed, S. S. S. J., Santosh, W., Kumar, S., & Christlet, H. T. T. (2009) · Journal of Biomedical Science · doi:10.1186/1423-0127-16-63 · Cited by 197
Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease
Franco-Iborra, S., Vila, M., & Perier, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00342 · Cited by 197
Coenzyme Q10 effects in neurodegenerative disease
Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 189
Mitochondria mass is low in mouse substantia nigra dopamine neurons: Implications for Parkinson's disease
Liang, C., Wang, T. T., Luby‐Phelps, K., & German, D. C. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.015 · Cited by 190
Platelet mitochondrial function: from regulation of thrombosis to biomarker of disease.
Zharikov, S. I., & Shiva, S. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120327 · Cited by 182
Genes, proteins, and neurotoxins involved in Parkinson’s disease
Halbach, O. V. B. U., Schober, A., & KRIEGLSTEIN, K. G. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.002 · Cited by 180
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses
Morris, G., Berk, M., Walder, K. R., & Maes, M. H. J. (2015) · BMC Medicine · doi:10.1186/s12916-014-0259-2 · Cited by 187
Mitochondrial Dysfunction in Parkinson's Disease
Keane, P. C., Kurzawa‐Akanbi, M., Blain, P. G., & Morris, C. M. (2011) · Parkinson s Disease · doi:10.4061/2011/716871 · Cited by 182
Mitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175
Autism Associated With the Mitochondrial DNA G8363A Transfer RNALys Mutation
Graf, W. D., Marı́n-Garcı́a, J., Gao, H.-G., Pizzo, S., Naviaux, R. K., Markusic, D. M., Barshop, B. A., Courchesne, E., & Haas, R. (2000) · Journal of Child Neurology · doi:10.1177/088307380001500601 · Cited by 174
Self-citation
Mitochondria Targeted Peptides Protect Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Neurotoxicity
Yang, L., Zhao, K., Calingasan, N. Y., Luo, G., Szeto, H. H., & Beal, M. F. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2445 · Cited by 168
Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas
Área-Gómez, E., Guardia‐Laguarta, C., Schon, E. A., & Przedborski, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120848 · Cited by 169
Human complex I defects in neurodegenerative diseases
Schapira, A. H. V. (1998) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00032-2 · Cited by 166
Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease
Haddad, D., & Nakamura, K. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.021 · Cited by 167
Mitochondrial Dysfunction in Parkinson's Disease
Zhu, J., & Chu, C. T. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100363 · Cited by 160
Dopamine‐Induced Apoptosis Is Mediated by Oxidative Stress and Is Enhanced by Cyanide in Differentiated PC12 Cells
Jones, D. C., Gunasekar, P. G., Borowitz, J. L., & Isom, G. E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742296.x · Cited by 156
Estrogen actions on mitochondria--physiological and pathological implications.
Simpkins, J., Yang, S.-H., Sarkar, S., & Pearce, V. P. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.04.013 · Cited by 155
A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
Tabrez, S. S. M., Jabir, N. R., Shakil, S., Greig, N. H., Alam, Q., Abuzenadah, A. M., Damanhouri, G., & Kamal, M. A. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712800792785 · Cited by 153
PPAR: a therapeutic target in Parkinson’s disease
Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 151
Local Melatoninergic System as the Protector of Skin Integrity
Slominski, A. T., Kleszczyński, K., Semak, I. V., Janjetović, Z., Zmijewski, M. A., Kim, T., Slominski, R. M., Reiter, R. J., & Fischer, T. W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151017705 · Cited by 148
Mitochondrial mechanisms of estrogen neuroprotection.
Simpkins, J., & Dykens, J. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.04.007 · Cited by 7
NRF2 Activation Restores Disease Related Metabolic Deficiencies in Olfactory Neurosphere-Derived Cells from Patients with Sporadic Parkinson's Disease
Cook, A. L., Vitale, A. M., Ravishankar, S., Matigian, N., Sutherland, G. T., Shan, J., Sutharsan, R., Perry, C., Silburn, P. A., Mellick, G. D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021907 · Cited by 145
Acetyl-l-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy
Zaitone, S. A., Abo–Elmatty, D. M., & Shaalan, A. A. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.002 · Cited by 141
Mitochondrial dynamics in Parkinson's disease
Laar, V. S. V., & Berman, S. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.019 · Cited by 141
High frequency of mitochondrial complex I mutations in Parkinson’s disease and aging
Smigrodzki, R. M., Parks, J. K., & Parker, W. D. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.020 · Cited by 138
M itochondrial DNA and primary mitochondrial dysfunction in P arkinson's disease
Giannoccaro, M. P., Morgia, C. L., Rizzo, G., & Carelli, V. (2017) · Movement Disorders · doi:10.1002/mds.26966 · Cited by 137
The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease
Cuadrado, A., Moreno-Murciano, P., & Pedraza‐Chaverrí, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/13543780802716501 · Cited by 135
Contribution of the Nrf2 Pathway on Oxidative Damage and Mitochondrial Failure in Parkinson and Alzheimer’s Disease
Villavicencio-Tejo, F., & Quintanilla, R. A. (2021) · Antioxidants · doi:10.3390/antiox10071069 · Cited by 143
Regulation of SIRT3 on mitochondrial functions and oxidative stress in Parkinson’s disease
Shen, Y., Wu, Q., Shi, J., & Zhou, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110928 · Cited by 135
Proteasomal inhibition induced by manganese ethylene-bis-dithiocarbamate: Relevance to parkinson′s disease
Zhou, Y. F., Shie, F., Piccardo, P., Montine, T. J., & Zhang, J. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.06.048 · Cited by 135
The interplay of neuronal mitochondrial dynamics and bioenergetics: Implications for Parkinson's disease
Laar, V. S. V., & Berman, S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.015 · Cited by 137
Targeting urate to reduce oxidative stress in Parkinson disease
Crotty, G. F., Ascherio, A., & Schwarzschild, M. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.06.017 · Cited by 134
Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease
Jin, J., Meredith, G. E., Chen, L., Zhou, Y. F., Xu, J., Shie, F., Lockhart, P. J., & Zhang, J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.10.003 · Cited by 129
Mitochondrial toxins in models of neurodegenerative diseases. I: in vivo brain hydroxyl radical production during sytemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions
Smith, T. S., & Bennett, J. P. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00429-0 · Cited by 129
CoQ10 and Aging
de Barcelos, I. P., & Haas, R. (2019) · Biology · doi:10.3390/biology8020028 · Cited by 129
Self-citation
Complex I: Inhibitors, inhibition and neurodegeneration
Schapira, A. H. V. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.028 · Cited by 123
Glucose Metabolic Dysfunction in Neurodegenerative Diseases—New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming
Han, R., Liang, J., & Zhou, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115887 · Cited by 125
Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease
Sato, S., Mizuno, Y., & Hattori, N. (2005) · Neurology · doi:10.1212/01.wnl.0000154597.24838.6b · Cited by 124
Preferentially Increased Nitration of α-Synuclein at Tyrosine-39 in a Cellular Oxidative Model of Parkinson’s Disease
Danielson, S. R., Held, J. M., Schilling, B., Oo, M. L., Gibson, B. W., & Andersen, J. K. (2009) · Analytical Chemistry · doi:10.1021/ac901176t · Cited by 123
Differential Cytotoxicity of Mn(II) and Mn(III): Special Reference to Mitochondrial [Fe-S] Containing Enzymes
Chen, J., Tsao, G. C., Zhao, Q., & Zheng, W. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9245 · Cited by 123
Mitochondrial DNA Deletions/Rearrangements in Parkinson Disease and Related Neurodegenerative Disorders
Gu, G., Reyes, P. F., Golden, G. T., Woltjer, R. L., Hulette, C., Montine, T. J., & Zhang, J. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.7.634 · Cited by 122
Oxidative α-Ketoglutarate Dehydrogenase Inhibition via Subtle Elevations in Monoamine Oxidase B Levels Results in Loss of Spare Respiratory Capacity
Kumar, M. J., Nicholls, D. G., & Andersen, J. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306378200 · Cited by 120

Authors: Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W.
Affiliations: University of California San Diego (US)
Veterans Health Administration (US)
ORCID: Haas, Richard H.
Nakano, Kazutoshi
Ward, David
Hill, Robert
Venue: Annals of Neurology
Publisher: Wiley
Published: 1995-06
Volume: 37
Issue: 6
Pages: 714-722
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410370604
OpenAlex: W2112777355
Cited by: 435
References: 47
Citations by year: 2026: 5 · 2025: 9 · 2024: 6 · 2023: 9 · 2022: 14 · 2021: 14 · 2020: 19 · 2019: 23 · 2018: 13 · 2017: 18 · 2016: 8 · 2015: 22 · 2014: 9 · 2013: 15 · 2012: 11
FWCI: 7.62
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 3417 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ns029504-03)
National Institute of Neurological Disorders and Stroke (R01 NS29504)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Keywords: Parkinson's disease, platelet mitochondria, mitochondrial electron transport chain, complex I, MPTP, etiology, mitochondrial dysfunction
MeSH terms: Adult, Aged, Blood Platelets, Citrate (si)-Synthase, Female, Humans, Male, Middle Aged, Mitochondria, Multienzyme Complexes, Oxidoreductases, Parkinson Disease, Smoking, Succinate Dehydrogenase, Electron Transport Complex III, NAD(P)H Dehydrogenase (Quinone), Electron Transport Complex II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks